Acquired haemophilia A: successful treatment of a patient using upfront immunosuppressive therapy and haemostatic agents.

ABSTRACT: Acquired haemophilia A (AHA) is a rare and possibly fatal autoimmune disorder that is challenging to treat. Although a majority of cases are idiopathic, AHA can also be associated with an underlying malignancy, autoimmune disorder, pregnancy, infection or certain medications. The diagnosis and treatment of AHA require a specialist with both clinical and laboratory expertise. The goal of treatment is aimed at achieving haemostasis as well as eradicating factor inhibitors. We present a patient with AHA and life-threatening haemorrhage who was successfully treated with a combination of haemostatic agents and a triple-drug immunosuppressive regimen. In reviewing recent studies and published guidelines, we advocate that a newer agent, emicizumab, can potentially be incorporated into the treatme

SUBMITTER: Chung SY 

PROVIDER: S-EPMC8217947 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature